Skip to content

Privacy Policy

Tirzepatidedosing does not collect personal data on this site. Analytics is aggregated and anonymous.

Reviewed by the Tirzepatidedosing Research Team · Last updated March 2026

References & Scientific Sources

  1. Coskun T, et al. Tirzepatide, a dual GIP/GLP-1 receptor agonist: mechanism. Mol Metab. 2018.
  2. Jastreboff AM, et al. Tirzepatide once weekly for obesity (SURMOUNT-1). N Engl J Med. 2022.
  3. Frias JP, et al. Tirzepatide vs semaglutide in type 2 diabetes (SURPASS-2). N Engl J Med. 2021.

Sources are provided for educational reference. This content is informational and not a substitute for professional medical advice.